# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Babe Didrikson Zaharias (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML038-SYN
- Date: 2026-10-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Vasquez-Thornbury, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Final restaging after nine doses of dostarlimab. **S**

## History of present illness

Ms. Didrikson Zaharias returns two weeks after her ninth and last dose of dostarlimab. Final restaging last week showed only fibrosis on MRI, no metastases on CT, and a flat white scar with no ulcer on sigmoidoscopy. She has had no bleeding, urgency or change in bowel habit for five months, and no diarrhea, rash, cough or breathlessness. She takes levothyroxine 75 micrograms each morning, has no tiredness or cold intolerance, and is still taking ferrous sulfate. The second hepatitis B vaccine dose was given with the last dose of dostarlimab. She played four tournaments over the summer and won a regional event last month. She asked what watch-and-wait means and how she will know if the cancer comes back. **S**

| Element | Detail |
|---|---|
| Treatment | Nine doses of dostarlimab over six months, completed two weeks ago |
| Restaging | MRI: complete response; CT: no metastases; sigmoidoscopy: flat white scar, no ulcer |
| Adverse events | Immune-related hypothyroidism, replaced; nothing else |
| Sport | Competing; won a regional event last month |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight 63.4 kg, steady |
| Gastrointestinal | Negative | Normal bowel movements; no bleeding, urgency or leakage |
| Endocrine | Negative | No cold intolerance or palpitations |
| Genitourinary | Negative | Sex comfortable; no urinary symptoms |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Negative | Relieved; some worry before each scan; PHQ-9 2, GAD-7 3; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning **S**
- Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from iron **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 64 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 63.4 kg; BMI 22.5 kg/m². All vital signs are synthetic.

Hemoglobin: 13.4 g/dL; MCV: 86 fL; White cell count: 6.1 10*3/uL; Platelets: 255 10*3/uL; Creatinine: 0.77 mg/dL; eGFR (CKD-EPI 2021): 99 mL/min/1.73 m²; ALT: 19 U/L; AST: 21 U/L; Ferritin: 41 ng/mL; TSH: 2.4 mIU/L; Free T4: 1.2 ng/dL; CEA: 1.6 ng/mL; PHQ-9: 2; GAD-7: 3. All results are synthetic.

## Change since baseline

- Hemoglobin: 11 g/dL (low) at baseline, 13.4 g/dL at this visit **S**
- MCV: 77 fL (low) at baseline, 86 fL at this visit **S**
- White cell count: 6.8 10*3/uL at baseline, 6.1 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 255 10*3/uL at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.77 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 98 mL/min/1.73 m² at baseline, 99 mL/min/1.73 m² at this visit **S**
- ALT: 18 U/L at baseline, 19 U/L at this visit **S**
- AST: 21 U/L at baseline, 21 U/L at this visit **S**
- Ferritin: 9 ng/mL (low) at baseline, 41 ng/mL at this visit **S**
- CEA: 5.8 ng/mL (high) at baseline, 1.6 ng/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Fit and well; weight 63.4 kg; blood pressure 112/70, pulse 64 |
| Neck | Thyroid not enlarged |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Abdomen | Soft, non-tender; no liver enlargement or mass |
| Rectal | With her agreement and a chaperone: smooth, supple wall; no mass, nodule or ulcer; normal sphincter tone; no blood |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Low rectal adenocarcinoma, mismatch repair deficient, after dostarlimab: clinical complete response** (C20). Clinical complete response on all three tests that define it: a normal rectal examination, a flat white scar without ulcer or nodularity on endoscopy, and only fibrosis without restricted diffusion on MRI; CT shows no metastases and CEA is 1.6 ng/mL. With the tumor board, she chose watch-and-wait: no radiation and no surgery, with close surveillance so that any regrowth can be removed early. She keeps her rectum and anus, and will not need a colostomy unless the tumor regrows. **S**
   - Watch-and-wait: rectal examination and sigmoidoscopy every three to four months and pelvic MRI every six months for two years.
   - CEA every three to six months; CT of the chest, abdomen and pelvis every six to twelve months; colonoscopy at one year.
   - Written survivorship care plan given today.
   - Screening advice for first-degree relatives repeated.
2. **Immune-related primary hypothyroidism on levothyroxine** (E03.2). TSH 2.4 mIU/L and free T4 1.2 ng/dL on levothyroxine 75 micrograms; symptoms gone. The TSH due with the ninth dose was not drawn. **S**
   - Continue levothyroxine 75 micrograms.
   - TSH in six months, then yearly.
3. **Iron deficiency anemia from rectal blood loss** (D50.0). Hemoglobin 13.4 g/dL and ferritin 41 ng/mL: anemia corrected and stores partly refilled. **S**
   - Ferrous sulfate for three more months, then stop.
   - Blood count with the next surveillance visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Final restaging pelvic MRI, CT of the chest, abdomen and pelvis, and flexible sigmoidoscopy | After the last dose | Up to date | Last week: complete response on MRI and endoscopy; no metastases on CT |
| Examination | Digital rectal examination | At each oncology visit during treatment; every three to four months in watch-and-wait | Completed today | Normal; no mass or ulcer |
| Laboratory | CEA | At diagnosis, at each restaging, then every three to six months for two years | Completed today | 1.6 ng/mL |
| Laboratory | Blood count | After treatment and with surveillance | Completed today | Hemoglobin 13.4 g/dL, MCV 86 fL, white cells 6.1, platelets 255 |
| Laboratory | Ferritin after oral iron | About three months after starting | Completed today | 41 ng/mL, drawn late (deviation recorded at the fourth visit) |
| Laboratory | Kidney and liver function | After PD-1 blockade | Completed today | Creatinine 0.77 mg/dL, eGFR 99; ALT 19, AST 21 U/L |
| Laboratory | TSH and free T4 | At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine change | Completed today | TSH 2.4 mIU/L, free T4 1.2 ng/dL on levothyroxine 75 micrograms |
| Laboratory | TSH and free T4 with the ninth dose | Every six weeks on PD-1 blockade | Deferred | Missed: the thyroid tests due with the ninth dose, six weeks after the preventive visit, were not on the infusion order. No harm resulted, since the TSH today, eight weeks after the last check, is in range on an unchanged dose; corrective action: thyroid tests added to her standing surveillance order set, and the infusion center's PD-1 order set reviewed so that thyroid tests repeat automatically every six weeks |
| Imaging | Pelvic MRI in watch-and-wait | Every six months for two to three years | Due | Next in six months |
| Imaging | Flexible sigmoidoscopy in watch-and-wait | Every three to four months for two years, then every six months to five years | Due | Next in three months |
| Imaging | CT of the chest, abdomen and pelvis | Every six to twelve months for five years | Due | Next in six to twelve months |
| Imaging | Colonoscopy | At one year | Due | Next in one year |
| Self-management | Survivorship care plan | Within a year of completing treatment | Completed today | Written treatment summary, surveillance schedule and warning signs given to her |
| Self-management | Bowel function (low anterior resection syndrome, incontinence) | After rectal surgery or radiation | Not indicated | No surgery or radiation; bowel function normal |
| Referral | Wound-ostomy nursing | If a stoma is created | Not indicated | No stoma |
| Self-management | Sexual function and fertility | Through survivorship | Completed today | Sex comfortable; contraception continued for four months after the last dose; not planning a pregnancy |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and at least yearly | Completed today | PHQ-9 2 (item 9 scored 0), GAD-7 3 |
| Self-management | Lifestyle: activity, diet and alcohol | Each visit | Completed today | Golf and strength work most days; red meat cut back; alcohol rare |

## Goal progress

- Colonoscopy within one week, staging within two weeks, and a tumor board plan before treatment. Outcome by 2026-03-30: Colonoscopy in three days, MRI and CT within nine days, tumor board in eleven days, consultation at two weeks. **S**
- Germline genetic testing with counseling, and an explanation of the mismatch repair deficiency, within four weeks of diagnosis. Outcome by 2026-04-27: Germline panel negative; two somatic MSH2 variants in the tumor explain the deficiency. **S**
- Clinical complete response after six months of dostarlimab, with the rectum and sphincter preserved. Outcome by 2026-10-05: Clinical complete response on MRI, endoscopy and examination after nine doses; watch-and-wait begun. **S**
- Hemoglobin of 12 g/dL or more and ferritin above 30 ng/mL. Outcome by 2026-10-05: Hemoglobin 13.4 g/dL and ferritin 41 ng/mL. **S**
- Back to tournament golf during treatment. Outcome by 2026-06-29: Playing 18 holes and entered in a club competition by the fourth visit. **S**
- TSH within the reference range on thyroid replacement. Outcome by 2026-08-10: TSH 3.1 mIU/L six weeks after levothyroxine began. **S**
- PHQ-9 below 10 throughout treatment. Outcome by 2026-10-05: PHQ-9 between 2 and 6. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026), National Comprehensive Cancer Network
- Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025), New England Journal of Medicine
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Rex DK, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016-1030 (PMID 28555630) (2017), U.S. Multi-Society Task Force on Colorectal Cancer
- CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026), Aether Forge

## Follow-up

- Sigmoidoscopy and examination in three months; MRI in six months; primary care review in three months with TSH at six months. **S**

